Evaluation of Norepinephrine Transporter Expression and Metaiodobenzylguanidine Avidity in Neuroblastoma: A Report from the Children's Oncology Group

Table 1

Characteristics of 82 patients with available tumor mRNA and of the subset of 27 patients with centrally reviewed MIBG diagnostic scans.

	Entire cohort; (𝑁=82)	Subset of patients centrally reviewed; (𝑁=27)
Median age (range)	11.9 months; (0.1–171.7 months)	33 months; (3.8–171.7 months)
Age > 18 months at diagnosis	35/82 (42.7%)	22/27 (81%)
Intermediate-risk group : High-risk group	31 : 51	0 : 27
Adrenal primary tumor	38/82 (46.3%)	16/27 (59%)
Stage 4 : Stage 4S : Localized tumors	39 : 7 : 36	15 : 2 : 10
MYCN-amplified tumor	15/82 (18.3%)	14/27 (51.8%)
Unfavorable histology	29/80 (36.3%)	24/26 (92.3%)
Elevated baseline urine catecholamines	20/31 (64.5%)^a	16/27 (59.3%)
MIBG avid tumor at diagnosis	53/82 (64.6%)^b	19/27 (70.3%)

^aAvailable only in patients with high-risk disease.
^bInstitutional report.